Authors:

Tianshu Liu¹, Yulong Zheng², Yi Feng¹, Yiyi Yu1, Wei Li¹, Cheng Xiao², Jiong Qian², Chenyu Mao², Ning Li², Michael Shi³, Chuan Qi³, Lei Chen³, Steven Yu³, Jenny Yao³, Lingmin Lu³, Jianming Wang³

¹Department of Medical Oncology, Zhongshan Hospital, Fudan University;

²Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine;

³Suzhou Transcenta Therapeutics Co., Ltd

Background:
• Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are key players in tumor angiogenesis signaling pathway. VEGF and VEGFR inhibitors have demonstrated clinical benefit in multiple cancer and eye diseases.
• MSB0254 is a humanized vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody which inhibits angiogenesis induced by either VEGF-A or –C.
• This is a phase I study to evaluate MSB0254’s safety, tolerability and PK profiles, as well as preliminary anti-cancer activities in Chinese patients with advanced solid tumors.

Conclusions and Future Directions of Research:

• MSB0254 demonstrated a manageable safety profile and preliminary antitumor activity in patients with advanced solid tumors. 16mk/kg Q2W and 20 mg/kg Q3W were recommended as RP2D.

• The study of MSB0254 on selected types of tumor warrants further investigation.